WHY IT MATTERS: As pharmaceutical companies advance synthetic and semi-synthetic endocannabinoid-targeted compounds through clinical trials, patients should understand that these pipeline drugs are distinct from currently available cannabis products and remain years away from prescription availability. CLINICAL OVERVIEW: The endocannabinoid system continues to attract serious pharmaceutical investment, with companies developing targeted drug candidates designed to modulate specific receptor pathways rather than relying on whole-plant cannabis preparations. This approach reflects a broader shift toward isolating and optimizing individual mechanisms within the endocannabinoid system, including CB1, CB2, and related receptor targets, for conditions where conventional treatments fall short.